Age- and ApoE genotype-dependent transcriptomic responses to O3 in the hippocampus of mice
Ontology highlight
ABSTRACT:
INSTRUMENT(S): Illumina NovaSeq X, Illumina® (NEB, USA)
ORGANISM(S): Mus musculus
SUBMITTER: Mary Frances Nakamya
PROVIDER: E-MTAB-14917 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
Similar Datasets
Project description:Chronic Stress and Western diet are major risk factors for affective disorders, however their biological interactions remain unclear. This study examined the neurochemical, mitochondrial, metabolic, behavioural and proteomic effects of a chronic stress paradigm (2h/day for 2 weeks) in male C57bl/6 mice fed either a control or Western diet for 20 weeks. This study showed that a Western diet induced metabolic dysfunction and depressive-like symptoms (reduce sucrose preference), but had minimal impact of frontal cortex or hippocampal mitochondrial or neurochemical measures. In contrast, chronic stress produced anxiety-like behaviour (via open field test measures), frontal cortex reductions in BDNF and GABA, elevated Glutamate and marked mitochondrial dysfunction. When combined, mice showed depressive-like behaviours despite similar neurochemical changes to that observed with stress alone. Proteomic analyses showed stress-related disruption of mitochondrial, synaptogenesis and NRF2 pathways, as well as adaptive responses to stress or Western diet that were reversed to maladaptive under co-morbid conditions. Finding implicate failed mitochondrial and synaptic adaptations in frontal cortex as key mechanisms linking stress-diet interactions to affective pathology.
2026-05-25 | PXD074187 | Pride
Project description:Here, we used laser microdissection combined with high-resolution mass spectrometry technology to construct the brain spatial proteomics map of AD mice and WT mice, aiming to identify the spatial protein distribution characteristics of Alzheimer's disease.
2026-06-02 | PXD055958 | Pride
Project description:Beyond the DNA sequence difference between humans and closely related apes, there are large differences in the environments that these species experience. One prominent example for this is diet. The human diet diverges from those of other primates in various aspects, such as having a high calorie and protein content, as well as being cooked. Here, we used a laboratory mouse model to identify gene expression differences related to dietary differences. Experiment Overall Design: We fed four groups of six genetically identical 8-week-old female NMR1 mice one of four diets ad libidum: (1) a diet consisting of vegetables, fruit and yogurt identical to the diet fed to chimpanzees in our ape facility ('Chimpanzee'); (2) a diet consisting exclusively of McDonalds. fast food ('FastFood'); (3) a diet consisting of cooked food eaten by our staff in the Institute cafeteria ('HumanCafe'); (4) the mouse pellet diet on which they were raised ('Pellet'). At the end of a 2-week period, mice were euthanized by cervical dislocation and both liver and brain (right cerebral hemisphere) tissue were dissected. RNA was extracted from the 24 liver and brain samples as per established lab protocols and processed in two batches (containing equal numbers of individuals from all groups).
2009-09-23 | E-GEOD-6285 | biostudies-arrayexpress
Project description:Parkinson’s disease (PD) is characterized by multiple symptoms including olfactory dysfunction, whose underlying mechanisms remain unclear. Here, we explored pathologic changes in the olfactory pathway of transgenic (Tg) mice of both sexes expressing the human A30P mutant α-synuclein (α-syn; α-syn-Tg mice) at 6–7 and 12–14 months of age, representing early and late-stages of motor progression, respectively. α-Syn-Tg mice at late stages exhibited olfactory behavioral deficits, which correlated with severe α-syn pathology in projection neurons (PNs) of the olfactory pathway. In parallel, olfactory bulb (OB) neurogenesis in α-syn-Tg mice was reduced in the OB granule cells at six to seven months and OB periglomerular cells at 12–14 months, respectively, both of which could contribute to olfactory dysfunction. Proteomic analyses showed a disruption in endocytic and exocytic pathways in the OB during the early stages which appeared exacerbated at the synaptic terminals when the mice developed olfactory deficits at 12–14 months. Our data suggest that (1) the α-syn-Tg mice recapitulate the olfactory functional deficits seen in PD; (2) olfactory structures exhibit spatiotemporal disparities for vulnerability to α-syn pathology; (3) α-syn pathology is restricted to projection neurons in the olfactory pathway; (4) neurogenesis in adult α-syn-Tg mice is reduced in the OB; and (5) synaptic endocytosis and exocytosis defects in the OB may further explain olfactory deficits.
2023-01-13 | PXD039396 | Pride
Project description:Remyelinating substances could be an essential supplement to immunomodulatory medications, optimizing the treatment of multiple sclerosis (MS) patients. Fingolimod is a sphingosine-1-phosphate receptor (S1PR) modulator and crosses the blood-brain barrier. Central nervous system (CNS) cells express S1PRs, and Fingolimod could theoretically improve CNS remyelination and be neuroprotective per se, but data are inconsistent. We used the cuprizone model for investigating the effect of fingolimod on remyelination and axonal damage by Immunohistochemistry and quantitative mass spectrometry. After three weeks of remyelination, fingolimod-treated mice had more mature oligodendrocytes in the secondary motor cortex than the placebo group. However, fingolimod did not at any time point affect remyelination or axonal damage. We conclude that fingolimod does not promote remyelination or protect against axonal injury or loss after cuprizone exposure.
2019-11-20 | PXD012676 | Pride
Project description:The goal of this study was to assess the number and types of differentially expressed genes in a transgenic (genomic) mouse model of tau pathology. Notably, we crossed previously described genomic mouse line called â8câ that expresses all isoforms of human tau protein (Duff et al., Neurobiology of Disease, 2000;7(2):87) with a mouse tau knockout line (Dawson et al., J Cell Sci 2001;114:1179) and generated humanized mice line called âhTau Dk/Dkâ. These mice are complete knockout of endogenous mouse tau and express all six isoforms of human tau driven by the endogenous human tau promoter. We performed microarray analysis in the hippocampal tissue from six-month old hTau Dk/Dk mice (n=3) and compared it with age-matched non-transgenic control group. Both the lines are in C57BL/6J genetic background.
2017-03-15 | E-MTAB-5078 | biostudies-arrayexpress
Project description:Traumatic brain injury (TBI) remains a leading cause of post traumatic epilepsy (PTE). Blast TBI (bTBI) found in Veterans presents cognitive and behavioral disturbance such as PTE, however, the underlying mechanisms that drive the long-term sequelae are not well understood. Using an unbiased proteomics approach in a murine model of repeated bTBI (rbTBI), this study addresses this gap in knowledge. Following rbTBI, mice underwent 24/7 EEG recording for four months before collecting the cortex and hippocampus of PTE+, PTE- and sham mice. Hundreds of differentially expressed proteins were identified in the cortex and hippocampus of PTE+ and PTE- relative to sham. Focusing on protein pathways unique to PTE+ animals revealed mitochondrial function, post translational modifications, and protein transport proteins were disrupted. Computational metabolic modeling using dysregulated protein expression predicted mitochondrial proton pump dysregulation, suggesting electron transport chain dysregulation in epileptic tissue relative to PTE- and sham. Finally, data mining enabled the identification of several novel and previously validated TBI and epilepsy biomarkers in our data set, many of which were found to already be targeted by drugs in various phases of clinical testing. These findings highlight novel proteins and protein pathways that may drive the chronic PTE sequala following rbTBI.
2024-06-22 | PXD048228 | Pride
Project description:Mice were bred such that they are homozygous for human MAPT (tau), and one of two versions of the APP gene (NL and NLF) referring to the Swedish familial Alazheimer's Disease (AD) variants, and one of human APOE allele E3 or APOE allele E4. APP-NLF+APOE(E3) mice develop amyloid plaques and attention and memory deficits at 16-24 months, whereas APP-NLF+APOE(E4) mice develop this phenotype earlier at 9 months. Three mice of each of the four possible genotypes were sacrificed at 9 months of age, and the prefrontal cortex was dissected and subject to single nucleus RNA sequencing (snRNAseq) with the 10X Chromium platform.
2025-10-07 | E-MTAB-15294 | biostudies-arrayexpress
Project description:The neuronal loss induced-brain atrophy is the direct cause of Alzheimer’s disease (AD), but hardly can be observed in rodent AD models, and the underlying mechanisms remain unclear. Cell cycle reentry induces post-mitotic neuronal death (CRND). Here, we found that Cyclin dependent kinase 3 (CDK3) which drives cell cycle re-entry from G0 to G1 phase transition highly expresses in AD patients’ brain, and positively correlates with AD Braak stage and frontal atrophy. However, most of the rodent laboratory mouse lines have a stop-code mutation in Cdk3 gene. We generated neuronal specifically human CDK3 overexpression transgenic mice and the premature termination codon mutation correction knock-in mice (Cdk3(561DM)), and crossed them with two classic AD mouse models: 5xFAD and Tau-PS19 mice. Exogenous hCDK3 or endogenous mCdk3 expression both induced massive neuronal death and hippocampal atrophy, accompanying with exacerbated impairments of LTP and cognition in AD mice. We also screened and developed a CDK3 kinase inhibitor BMX330, which alleviated neuronal death and cognitive impairments in hCDK3-overexpressed mice. The multi proteomics and phosphoproteomics analyses of hCDK3 substrates further revealed that the CRND and synaptic dysfunctions are involved in CDK3 mediated neuronal loss. Our finding not only provide new evidence on the neuronal death mechanism of AD, but also created new AD mouse models which exhibit comprehensive AD-relevant pathological characteristics, particularly, neuronal death and brain atrophy. They may serve as useful tools in facilitating both AD research and drug discovery.
2025-10-27 | PXD046376 | Pride
Project description:The neuronal loss induced-brain atrophy is the direct cause of Alzheimer’s disease (AD), but hardly can be observed in rodent AD models, and the underlying mechanisms remain unclear. Cell cycle reentry induces post-mitotic neuronal death (CRND). Here, we found that Cyclin dependent kinase 3 (CDK3) which drives cell cycle re-entry from G0 to G1 phase transition highly expresses in AD patients’ brain, and positively correlates with AD Braak stage and frontal atrophy. However, most of the rodent laboratory mouse lines have a stop-code mutation in Cdk3 gene. We generated neuronal specifically human CDK3 overexpression transgenic mice and the premature termination codon mutation correction knock-in mice (Cdk3(561DM)), and crossed them with two classic AD mouse models: 5xFAD and Tau-PS19 mice. Exogenous hCDK3 or endogenous mCdk3 expression both induced massive neuronal death and hippocampal atrophy, accompanying with exacerbated impairments of LTP and cognition in AD mice. We also screened and developed a CDK3 kinase inhibitor BMX330, which alleviated neuronal death and cognitive impairments in hCDK3-overexpressed mice. The multi proteomics and phosphoproteomics analyses of hCDK3 substrates further revealed that the CRND and synaptic dysfunctions are involved in CDK3 mediated neuronal loss. Our finding not only provide new evidence on the neuronal death mechanism of AD, but also created new AD mouse models which exhibit comprehensive AD-relevant pathological characteristics, particularly, neuronal death and brain atrophy. They may serve as useful tools in facilitating both AD research and drug discovery.
2025-10-27 | PXD048032 | Pride